All In Biotech

Drug Trial Radar · NCT06511570

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

A Phase 1, Open-Label Study Comparing the Safety, Tolerability, and Pharmacokinetics of Single-Dose Intravenous Sabirnetug (ACU193) and Multiple-Dose Subcutaneous Sabirnetug (ACU193) + rHuPH20 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jun 25, 2024

Primary completion

Sep 17, 2024

Study completion Sep 17, 2024

Sponsor

Lead sponsor
Acumen PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Conditions

  • Alzheimer Disease

Interventions

  • sabirnetug (ACU193)Drug

    sabirnetug by intravenous infusion

  • Sabirnetug + rHuPH20Combination product

    sabirnetug + rHuPH20 by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate blood levels of sabirnetug (ACU193)Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  2. Estimate time to reach maximum blood levels of sabirnetug (ACU193)Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  3. Estimate blood levels of sabirnetug (ACU193), terminal rateTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  4. Estimate time to reach half-life blood levels of sabirnetug (ACU193), half-lifeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  5. Estimate blood levels of sabirnetug (ACU193), concentration-timeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  6. Estimate blood levels of sabirnetug (ACU193), last concentration-timeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  7. Estimate blood levels of sabirnetug (ACU193), infinity concentration-timeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  8. Estimate blood levels of sabirnetug (ACU193), extrapolationTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  9. Estimate blood levels of sabirnetug (ACU193), ClastTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
  10. Estimate time to reach last blood levels of sabirnetug (ACU193)Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.